Skip to content

About
Science
Newsroom
Careers
Contact

Menu

About
Science
Newsroom
Careers
Contact

Current News

Newsroom

Current News
Press Releases
Media
Scientific Publications

Latest Press Releases

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Idiopathic Pulmonary Fibrosis Trial using TTI-101, a Novel STAT3 Inhibitor

August 31, 2023

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor

June 22, 2023

Latest Media

New Phase 2 Study Set to Evaluate Oral TTI-101 in IPF

January 13, 2023

FDA Grants Fast Track Designation to TTI-101 for Advanced Hepatocellular Carcinoma

October 19, 2022

Latest Scientific Publications

Drugging “Undruggable” Disease-Causing Proteins: Focus on Signal Transducer and Activator of Transcription (STAT) 3

December 31, 2022

Genetic and Small-Molecule Modulation of Stat3 in a Mouse Model of Crohn’s Disease

November 28, 2022

Home
About
Our Science
Newsroom
Contact
FCOI
Privacy Policy
Terms of Use

Home
About
Our Science
Newsroom
Contact
FCOI
Privacy Policy
Terms of Use

Linkedin Twitter

Tvardi Therapeutics ©2023

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and Terms of Use.